Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations
可测量残留病灶 (MRD) 对维奈托克联合去甲基化药物治疗急性髓系白血病患者的预后价值:ELN-2021 MRD 建议的验证
期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-025-01298-6
Jimenez-Vicente, Carlos; Cardus, Aina; Castaño-Diez, Sandra; Ramil, Guillermo; Garcia-Avila, Sara; Gomez-Perez, Lucia; Esteban, Daniel; Arribas, Iago; Sturla, Antonella Lucia; Lopez-Guerra, Monica; Martinez-Roca, Alexandra; Cortes-Bullich, Albert; Perez-Valencia, Amanda Isabel; Zugasti, Ines; Monge, Ines; Carcelero, Esther; Vall-Llovera, Ferran; Vives, Susana; Sierra, Jorge; Nomdedeu, Josep; Oñate, Guadalupe; Garrido, Ana; Pratcorona, Marta; Pomares, Helena; Arnan, Montserrat; Guijarro, Francesca; Diaz-Beya, Marina; Esteve, Jordi